Senti Biosciences (NASDAQ:SNTI – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Senti Biosciences to related businesses based on the strength of its dividends, profitability, analyst recommendations, institutional ownership, valuation, earnings and risk.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Senti Biosciences and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 1 | 1 | 2.67 |
| Senti Biosciences Competitors | 9941 | 15335 | 45756 | 1605 | 2.54 |
Senti Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 10,244.83%. As a group, “Biotechnology” companies have a potential upside of 134.57%. Given Senti Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than its rivals.
Risk and Volatility
Insider and Institutional Ownership
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Senti Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Senti Biosciences | $20,000.00 | -$61.44 million | -0.05 |
| Senti Biosciences Competitors | $705.19 million | $8.07 million | -18.47 |
Senti Biosciences’ rivals have higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Senti Biosciences and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -1,629.80% | -119.72% |
| Senti Biosciences Competitors | -12,224.75% | -204.85% | -31.52% |
Summary
Senti Biosciences rivals beat Senti Biosciences on 7 of the 13 factors compared.
Senti Biosciences Company Profile
Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
